Combining two treatments for patients with certain solid tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This open-label, single-arm clinical trial evaluates the safety and efficacy of combining 177Lu-TLX250, a radioactive treatment, with peposertib in patients with carbonic anhydrase IX (CAIX) expressing solid tumors. The study consists of two parts: a dose escalation phase to determine the optimal dosing of both treatments, followed by a dose expansion phase focusing on patients with advanced renal cell carcinoma and other CAIX-positive solid tumors. Patients will receive treatment over three cycles, each lasting 84 days, and will be monitored for progression and toxicity.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Histologically confirmed advanced or metastatic solid tumor that has progressed on or during/after recognized standard of care therapies and are not eligible for resection, or patients that are not eligible or not consenting to recognized standard of care therapies.
* At least one measurable lesion on CT/MRI according to RECIST 1.1 with corresponding 89Zr-TLX250 uptake (i.e., CAIX positive).
* CAIX positivity in at least 75% of the total lesion volume (defined as 89Zr- TLX250 uptake with intensity significantly greater than normal liver \[i.e., standardized uptake value \[SUV\]max at least 1.5 times SUV of normal liver\]).
* ECOG status 0 or 1.
* Have adequate organ function during screening
* Must have a life expectancy of at least 6 months.

Exclusion Criteria:

* Prior 177Lu-TLX250 or other radioligand therapy; or any prior CAIX targeting therapy.
* Known hypersensitivity to compounds of similar chemical or biologic composition to peposertib, girentuximab radiolabelled by zirconium or lutetium, any excipient in the study medication or any other intravenously administered human proteins/peptides/antibodies.
* Administration of any radionuclide within 10 half-lives of the radionuclide prior to signature of the ICF.
* Patients who have had chemotherapy, definitive radiation, biological cancer therapy, or investigational agent/device within 28 days of first planned dose of study therapy.
* Patients who had \> 2 prior lines of cytotoxic chemotherapy or had Grade 4 neutropenia or Grade 3/Grade 4 thrombocytopenia (both of a duration of at least 48 hours) during the last line of therapy. Note: This criterion may be removed in total or in part by the SRC upon review of the safety data from the initial dose level(s).
* Patients who cannot discontinue concomitant medications or herbal supplements that are strong inhibitors or strong inducers of cytochrome P450 (CYP) isoenzymes CYP3A4/5, CYP2C9, and CYP2C19. Concomitant use of CYP3A4/5 substrates with a narrow therapeutic index are also excluded.
* Patients who cannot discontinue concomitant H2-blockers or proton-pump inhibitors (PPIs). Patients may confer with the investigator to determine if such medications can be discontinued. These must be discontinued ≥ 5 days prior to study treatment. Patients do not need to discontinue calcium carbonate.
* Patients who are receiving therapeutic doses of anticoagulation, including but not limited to low-molecular weight heparin in therapeutic dosing or platelet aggregation inhibitors. Note: This criterion may be removed by the SRC upon review of the safety data from the initial dose level(s).
* Patients with ≥ 5 bone metastases and/or bulky (\> 3cm in diameter) pelvic or femoral tumors, and/or metastases/tumor in the vertebral spine involving \> 3 vertebrae.
* Any severe concomitant condition which makes it undesirable for the patient to participate in the study or which could jeopardize compliance with the protocol, in the opinion of the investigator.
* Presence of active and uncontrolled infections or other severe concurrent disease, which, in the opinion of the investigator, would place the patient at undue risk or interfere with the study.
* Requirement of concurrent use of other anti-cancer treatments or agents other than study medications. Supportive care therapies are permitted.

Where it's running

• Macquarie University
  North Ryde, New South Wales, Australia Recruiting
• Ashford (Icon) Cancer Centre
  Adelaide, Australia Recruiting
• Princess Alexandra Hospital
  Brisbane, Australia Recruiting
• Austin Health
  Melbourne, Australia Recruiting
• GenesisCare Murdoch
  Perth, Australia Recruiting

Study contacts

• Study coordinator: Medical Director, Md

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Imaging with 89Zr-DFO-YS5 to detect cancer

  This study tests a new PET radiotracer, 89Zr-DFO-YS5, to see if it can show cancer sites in adults with nerve sheath tumors, bladder cancer, or other solid tumors.

  Recruiting Phase 1 University of California, San Francisco · San Francisco, California · NCT07664397

• Evaluating NKT3964 for Adults with Advanced Solid Tumors

  This study is testing a new drug called NKT3964 to see if it can safely help adults with advanced solid tumors, like ovarian or triple-negative breast cancer, after other treatments have failed.

  Recruiting at 17 sites Phase 1 NiKang Therapeutics, Inc. · Little Rock, Arkansas and 20 other locations · NCT06586957

• Using a radiotracer to detect granzyme B in advanced cancers

  This study is testing a new imaging tool to see if it can help find specific markers in advanced cancers, especially in patients with kidney and prostate cancer, to better understand how their tumors respond to treatment.

  Recruiting Phase 1/2 University of California, San Francisco · San Francisco, California · NCT05888532

• SGT003 in people with advanced solid tumors

  This early-phase study tests SGT003 in adults with advanced solid tumors to see if it is safe and tolerable and to get a first look at how it behaves in the body and any early signs of benefit.

  Recruiting Phase 1/2 Beijing Sungen Biomedical Technology Co., Ltd · Beijing, Beijing Municipality · NCT07811037

• YSCH-01 Nebulized Therapy for Lung Metastases in NSCLC and Advanced Solid Tumors

  A first-in-human, early-phase study tests a nebulized therapy called YSCH-01 to see if it is safe and shows any signs of benefit for adults with NSCLC or other cancers that have spread to the lungs.

  Recruiting Early Phase 1 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing · NCT07793500

• Personalized neoantigen-pulsed dendritic cell injections for malignant solid tumors

  This study tests personalized dendritic cell injections, with or without immune checkpoint inhibitors, to see if they are safe and can help patients with advanced solid tumors.

  Recruiting ZSky Biotech Inc · Qinhuangdao, Hebei · NCT07752953

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.